Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
Nov 20, 2026, 17:20

Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP

Dhinesh Selvaraju, Clinical Pharmacist at Thanthai Periyar Government Headquarters Hospital, shared a post on LinkedIn:

“FDA Approval (2025): Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric Acquired TTP

Introduction

On December 23, 2025, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Cablivi (caplacizumab-yhdp), extending its use to pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP).

This marks the first FDA-approved treatment option specifically for pediatric patients with aTTP.

Indication

Caplacizumab is indicated for adults and pediatric patients aged 12 years and older with aTTP, in combination with therapeutic plasma exchange and immunosuppressive therapy.

Mechanism of Action

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment. It binds to the A1 domain of vWF, preventing its interaction with platelet glycoprotein Ib.

This inhibits vWF-mediated platelet adhesion and microthrombus formation, a key process contributing to the pathophysiology of aTTP.

Clinical Evidence

The pediatric indication expansion was supported by a retrospective chart review involving 30 patients aged 2–18 years.
80% achieved clinical remission.

Clinical remission was defined by normalization of platelet count and LDH below 1.5 times the upper limit of normal, sustained for at least 30 days.

The evidence was observational rather than derived from a randomized pediatric controlled trial.

Safety and Monitoring

The principal safety concern is bleeding, which can be serious or fatal.

Important considerations include:

  • Monitor for mucosal and other clinically significant bleeding.
  • Exercise caution with concomitant anticoagulants and antiplatelet agents.
  • Withhold treatment for 7 days before elective surgery or invasive procedures.
  • Common adverse reactions include epistaxis and gingival bleeding.

Why this approval is important

This regulatory expansion extends access to a targeted anti-vWF therapy for adolescents with aTTP, a rare and potentially life-threatening thrombotic microangiopathy.

It also highlights the importance of integrating targeted inhibition of platelet adhesion with plasma exchange and immunosuppressive treatment in aTTP management.

References

  • U.S. FDA. FDA Approves Therapy for Rare Blood Disorder in Pediatric Patients 12 Years and Older. January 5, 2026.
  • U.S. FDA. CABLIVI Supplement Approval Letter, BLA 761112/S-018. December 23, 2025.
  • HCPLive. FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP Therapy. January 2026.”

Dhinesh Selvaraju

Stay updated with Hemostasis Today.